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Human Cytomegalovirus (CMV) is a well-recognized pathogen in the context of HIV
infection, but since the roll out of ART, clinical and scientific interest in the problem of
HIV/CMV coinfection has diminished. However, CMV remains a significant cofactor in
HIV disease, with an influence on HIV acquisition, disease progression, morbidity, and
mortality. Disease manifestations may be a result of direct interplay between the two
viruses, or may arise as a secondary consequence of immune dysregulation and systemic
inflammation. The problem is most relevant when the rates of coinfection are high, most
notably in sub-Saharan Africa, and in children at risk of acquiring both infections early
in life. Understanding the interplay between these viruses and developing strategies to
diagnose, treat and prevent CMV should be a priority.
Keywords: HIV-1, CMV, coinfection, sub-Saharan Africa, pediatric infectious diseases, immune activation,
antiretroviral therapy
Introduction
Human cytomegalovirus (CMV) is a ubiquitous β-herpesvirus, also known as HumanHerpes Virus
5 (HHV5). It is the largest of the human herpesviruses with a 230 kb genome encoding 165 genes.
CMV is widely recognized as an opportunistic pathogen, and has a high profile as an agent of
disease in immunocompromised patients; much of the recent research literature addresses infection
in those undergoing solid organ and bone marrow transplantation (Crough and Khanna, 2009;
Gracia-Ahufinger et al., 2015; Itzykson et al., 2015; Stevens et al., 2015).
CMV disease in the context of HIV is equally well-established, although interest in the
manifestations of coinfection has substantially diminished in the ART era. However, the complex
interplay between these two chronic viral infections continues to be potentially highly significant,
both in adults and children, and particularly in certain vulnerable populations, including sub-
Saharan Africa, where both CMV and HIV are endemic in neonates and children, leading to a risk
of coinfection in utero and during the earliest days of life (King et al., 2013). There has recently been
Abbreviations: HIV, Human Immunodeficiency Virus (denotes HIV-1); CMV, Cytomegalovirus; HHV5, Human Herpes
Virus-5; ART, Antiretroviral Therapy; MSM,Men who have Sex with Men; HEU, HIV Exposed Uninfected; AICD, Activation
Induced Cell Death; PMTCT, Prevention of Mother-To-Child Transmission.
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a revival of interest in CMV as a cofactor for HIV infection and
expert opinion has drawn attention to this somewhat neglected
topic in the literature (Emery, 2014).
We have therefore set out to review the epidemiology,
immunology and clinical impact of CMV infection in the setting
of co-infection with HIV, focusing particularly on it’s impact in
southern African populations—especially in children who are at
high risk of acquiring both infections within the first year of life.
We performed a PubMed search to identify reports of
HIV/CMV coinfection, particularly representing studies
conducted in sub-Saharan Africa. We have restricted references
to focus primarily on publications from within the last 10 years.
As there is a paucity of data from Africa, we have also cited
studies of other populations where they raise points that are of
particular relevance.
Epidemiology of CMV Mono- and
Co-infection
Transmission and Risk Factors
CMV can be transmitted via saliva, sexual contact, placental
transfer, breastfeeding, blood transfusion, and transplantation of
solid-organs or haematopoietic stem cells. In African studies,
factors including poor nutrition and low weight (Tembo et al.,
2015), crowded living conditions (Alao et al., 2009) and other
herpes virus coinfections (Schaftenaar et al., 2014) are associated
with increased CMV seroprevalence. Maternal CMV viraemia
during pregnancy is a risk factor for perinatal CMV transmission
(Munro et al., 2005).
In the Western world, the rate of CMV seropositivity is
much higher among adults with risk factors for acquisition of
HIV infection, for example MSM (Gianella et al., 2015), than
in the general population. Likewise, in a West African cohort,
increased CMV seropositivity has also been demonstrated in
HIV-positive individuals compared to HIV-uninfected controls
(Compston et al., 2009). These observations all suggest shared
risk factors for acquisition of the two viruses (e.g., lifestyle,
behavior, demographics) as well as raising the possibility that
HIV infection may be a direct risk factor for CMV acquisition
in adults. The reciprocal scenario may also apply, as recent
data from Africa suggest that CMV infection may be a risk
factor for HIV transmission; a study in KwaZulu-Natal found
an independent association between CMV in breast milk and
postnatal mother-to-child transmission of HIV (Viljoen et al.,
2015).
Seroprevalence in Adults and Children
In the USA, Australia and Europe, CMV seroprevalence among
adults is variable, estimated at between 36 and 77%; in
contrast, CMV is highly endemic in developing countries and
in particular in sub-Saharan Africa, with a seropositivity rate
that often approaches 100% in adults (Chakraborty et al.,
2003; Schlesinger et al., 2005; Miles et al., 2007, 2008; van
der Sande et al., 2007; Zhang et al., 2007; Dar et al., 2008;
Alao et al., 2009; Compston et al., 2009; Micol et al., 2009;
Pass et al., 2009; Cannon et al., 2010; Chakravarti et al., 2010;
Fielding et al., 2011; Brantsæter et al., 2012; Hsiao et al., 2013;
Manicklal et al., 2013, 2014; Gumbo et al., 2014; Lanzieri
et al., 2014; Mwaanza et al., 2014; Schaftenaar et al., 2014;
Lichtner et al., 2015; Tembo et al., 2015; Viljoen et al., 2015)
(Figure 1).
Congenital CMV accounts for a significant burden of
morbidity, including sensorineural deafness, developmental
delay, and intrauterine growth retardation. This is estimated
to affect 0.2–3% of live births in Western Europe and up to
14% in developing countries (Schlesinger et al., 2005; Zhang
et al., 2007; Cannon et al., 2010; Manicklal et al., 2013, 2014;
Gumbo et al., 2014; Mwaanza et al., 2014). The prevalence of
congenital CMV in different African populations is likely to vary;
data are sparse but studies range from rates of 2.9% in South
Africa (Manicklal et al., 2014), to 3.8% in Zambia (Mwaanza
et al., 2014), and 5.4% in the Gambia (van der Sande et al.,
2007). Subsequently, almost two thirds of infants in African
studies show serological evidence of infection by 3 months of
age and 85% are infected by a year (Miles et al., 2007; Gumbo
et al., 2014). By adolescence, CMV IgG is thought to be virtually
universal in sub-Saharan African populations (Chakraborty et al.,
2003).
In resource-poor settings, a large proportion of children
undergo simultaneous primary HIV and CMV infection (Miles
et al., 2007; Slyker et al., 2009). Thus, among HIV-positive
children in Africa, the majority are coinfected with CMV by
their first birthday (Miles et al., 2008; Gumbo et al., 2014),
and almost all are coinfected by the time they reach their
teens (Chakraborty et al., 2003). The growing epidemic of
coinfected adolescents may have significant clinical impact
in these populations. In comparison, a study from North
America reports a lower—although still substantial—rate of
early coinfections, finding that 40–50% of HIV/CMV-coinfected
children had acquired CMV before their first birthday (Kovacs
et al., 1999).
CMV infection is more common in neonates with HIV
infection compared with HEU infants; to date it has not been
possible to determine what proportion of CMV infections were
acquired in utero (Tembo et al., 2015). Several mechanisms
may explain the increased prevalence of CMV in HIV-infected
neonates; first, HIV-infected mothers who transmitted HIV in
utero would be expected to be more immunosuppressed and
therefore at increased risk of reactivating and transmitting
CMV. Second, immunosuppression associated with fetal HIV
infection may result in higher risk of CMV acquisition in
utero. Alternatively, fetal CMV coinfection may facilitate HIV
acquisition in utero (Slyker et al., 2009).
Immune Control of CMV
CMV immune control is multifactorial and there is evidence to
suggest that CD8+ and CD4+ T cells, NK cells and antibody-
mediated immunity all play a role in containment. We have
summarized the key elements in Figure 2, highlighting the
complex interplay of multiple limbs of the immune system
in containing CMV infection. When any component of this
immune control is aberrant, there is an increased risk of disease
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FIGURE 1 | Worldwide CMV seroprevalence rates in adults. We have represented studies of adults aged 16–50 years published between 2005 and 2015 from
Australia, Belgium, Brazil, Canada, Cambodia, Chile, China, Finland, France, Gambia, Germany, Ghana, India, Israel, Italy, Japan, Kenya, Mexico, Nigeria, Panama,
South Africa, Spain, Sweden, Taiwan, Tanzania, Turkey, UK, USA, Zambia, and Zimbabwe (Chakraborty et al., 2003; Schlesinger et al., 2005; Miles et al., 2007, 2008;
van der Sande et al., 2007; Zhang et al., 2007; Dar et al., 2008; Alao et al., 2009; Compston et al., 2009; Micol et al., 2009; Pass et al., 2009; Cannon et al., 2010;
Chakravarti et al., 2010; Fielding et al., 2011; Brantsæter et al., 2012; Hsiao et al., 2013; Manicklal et al., 2013, 2014; Gumbo et al., 2014; Lanzieri et al., 2014;
Mwaanza et al., 2014; Schaftenaar et al., 2014; Lichtner et al., 2015; Tembo et al., 2015; Viljoen et al., 2015).
either due to primary CMV or reactivation of latent CMV, both
of which can lead to disease manifestations.
There is also evidence that CMV can impact on
immunological development, both in children and in adults
(Ben-Smith et al., 2008; Miles et al., 2008a,b). In one study of
adolescents, the CMV-positive group (mostly from Malawi) had
fewer naïve CD4+ and CD8+ T cells and more differentiated
memory T cells than CMV-negative subjects (Ben-Smith et al.,
2008). This immunological phenotype is in keeping with that
normally seen in older adults and equates with less robust T
cell responses to new pathogens. Interestingly, CMV infection
may also have a beneficial effect on immune responses to other
pathogens: there are data from the Gambia suggesting that CMV
infection can promote active T-cell responses in infancy, leading
to more robust CD8+ responses to measles immunization and to
staphylococcal enterotoxins (Miles et al., 2008).
Immunopathology of HIV/CMV Coinfection
One African study reports a strong correlation between peakHIV
viral load and peak CMV viral load (Slyker et al., 2009). There
are several possible explanations for this. First, a direct influence
may operate between HIV and CMV viraemia, although it
is impossible to infer causation or the direction of such a
relationship: whether symptomatic CMV disease is a cause or
effect of high HIV-p24 antigen concentration is not known.
Second, it is also likely that there is an indirect effect, whereby
systemic inflammation fuels the replication of both viruses
(Griffiths, 2006). Finally, similar host factors may affect the
containment of both viruses. Several direct influences of CMV
on HIV have been proposed, as follows:
Increased Infection of CD4+ T Cells by HIV
In vitro investigations suggest a synergistic effect of CMV
and HIV in infecting CD4+ T cells and mediating immune
suppression. CMV does not itself infect CD4+ T cells, but may
enhance the uptake of HIV into these cells by several different
mechanisms:
• The US28 gene of CMV encodes a chemokine receptor
that can act as a substitute for the HIV receptor CCR5, so
facilitating entry of HIV into CD4+ T cells (Pleskoff et al.,
1997).
• CMV encodes a molecule which can act as an alternative
receptor for HIV; HIV coated in non-neutralizing antibodies
can gain access to fibroblasts via this CMV-encoded Fc
receptor (McKeating et al., 1990). However, the significance
of this process is uncertain, as fibroblasts do not support
productive HIV infection.
• Active CMV infection can alter the cell tropism of HIV in
dually infected individuals by facilitating HIV DNA entry into
ordinarily non-permissive human fibroblasts (Margalith et al.,
1995). For example, activation induced by CMV upregulates
expression of CCR5 in CD4+ T central memory cells and
facilitates in utero transmission of HIV (Johnson et al., 2014).
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FIGURE 2 | Impact of the immune system on CMV. CMV immune control is reliant on both the innate and adaptive arms of the immune system. We have here
summarized the key elements, highlighting the complex interplay of multiple limbs of the immune system in containing CMV infection.
Re-activation of Latent HIV
CMV may activate latent proviral HIV DNA by several
different mechanisms at the molecular level, briefly
outlined below, and also explored by other reviews
(Griffiths, 2006):
• The CMV IE-2 gene can augment HIV gene expression within
the same cell (Davis et al., 1987).
• CMV infection causes release of cytokines from a
bystander cell, activating latent HIV provirus through
signal transduction (Clouse et al., 1989).
• Exposure to CMV antigen from a bystander cell could
promote activation of latent HIV in a T memory cell whose
cognate antigen receptor is CMV-specific (Peterson et al.,
1992).
• Intermediate and early CMV genes can increase HIV
expression by induction of NF-kappa B transcription factor,
activating transcription from a stably expressed HIV-1 long
terminal repeat (Davis et al., 1987).
• CMV upregulates cytokines including IL-2, IL-6, and TNFa
that may contribute to inducing HIV replication (Osborn
et al., 1989).
Cellular Immune Activation and Apoptosis
Cellular activation caused by CMV contributes to HIV
pathogenesis by depletion of T cells via apoptosis induced cell
death (AICD) (Slyker et al., 2012). Apoptosis is a hallmark of
HIV infection and increased AICD is thought to contribute to
the gradual loss of CD4+ helper cells during progression toward
AIDS. The CD95/APO-1/Fas receptor/ligand system is critically
involved in induction of apoptosis (Böhler et al., 2001; Cummins
and Badley, 2010). Dysregulation of this system contributes to
increased AICD of T cells in HIV infection and is associated
with disease progression (Sloand et al., 1997; Silvestri et al., 1998;
Böhler et al., 2001; Cummins and Badley, 2010).
In a cohort of Kenyan HIV-infected infants, the frequencies
of activated (CD38+ HLA-DR+) and apoptosis vulnerable
(CD95+Bcl-2-) CD4+ and CD8+ T cells increased substantially
during acute CMV infection (Slyker et al., 2012). Similar
observations were made in HEU infants (Slyker et al.,
2012). These data support the hypothesis that CMV-induced
T cell activation and Fas-mediated apoptosis potentially
contribute to the increased HIV disease progression observed
particularly in CMV coinfected infants (Kovacs et al.,
1999).
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Clinical Consequences of CMV/HIV
Coinfection
In the pre-ART era, end-organ disease caused by CMV
was the most common presentation of HIV infection,
particularly retinitis at absolute CD4+ T cell counts <50/mm3.
These manifestations are now much less frequent as ART
successfully preserves CD4 counts, but the more subtle
immune dysregulation associated with HIV-CMV coinfection
is now recognized as a cause for concern. There is good
evidence to support the relationship between CMV infection
and increased disease progression and mortality in HIV
infection (Table 1). However, it remains unknown whether
acquisition or reactivation of CMV infection are markers of
the immune dysfunction associated with HIV replication, or
whether CMV infection itself is a co-factor that promotes
HIV progression. These potential pathways are summarized
by Figure 3, highlighting the cross-talk between CMV and the
immune system.
In Western settings, active CMV disease in HIV-infected
patients has significantly declined in the ART era (Chakravarti
et al., 2010), perhaps providing false reassurance that CMV
is not a relevant co-pathogen. However, in resource poor
settings, including many parts of sub-Saharan Africa, there
are few data to inform our understanding of clinical interplay
between CMV and HIV. Furthermore, there is increasing
evidence to suggest that CMV remains a relevant co-factor
in disease progression in individuals with HIV, irrespective of
ART (Riou et al., 2015), highlighted by the following three
points:
Accelerated Rate of Progression of HIV
Progression to an AIDS-defining event has been significantly
and independently associated not only with HIV RNA viral
load and CD4+ T cell count, but also with CMV DNA
(Erice et al., 2003; Fielding et al., 2011). In a population of
HIV-infected hemophiliacs, coinfection with CMV adversely
influenced the course of the disease; in particular, the age-
adjusted relative risk of developing AIDS in CMV-seropositive
patients was 2.5 times that in CMV seronegatives (Webster
et al., 1989). Conversely, ART dramatically reduces HIV
replication, so delaying the development of immunocompromise
and disease. Immune reconstitution secondary to ART results
in a significant and progressive decline in blood CMV
viraemia even in the absence of specific anti-CMV therapy
(Connick, 2001).
Mortality
In studies conducted in developed countries, detectable CMV
DNA in plasma (Wohl et al., 2005) or in whole blood (Deayton
et al., 2004; Reus et al., 2004) have been shown to be independent
predictors of death even after adjusting for HIV RNA level or
CD4+ T cell count. Strikingly, a recent study of HIV-positive
adults in rural Tanzania that used dried blood spots to detect
CMV viraemia found a hazard ratio of 5 for mortality in the
presence of CMV (Brantsæter et al., 2012).
TABLE 1 | Association between CMV infection and disease progression
and mortality in HIV infection in African children.
Author Publication
Year
Study
Location
Population
Studied
Findings
Vilioen 2015 South
Africa
124
HIV-infected
mothers and
their babies
CMV is associated with
increased HIV shedding
in breast milk
Gumbo 2014 Zimbabwe 257
ART-naïve
HIV-positive
infants
79% CMV IgG positive
by age 6 weeks. No
increase in mortality
associated with CMV
Tembo 2015 Zambia 303 pediatric
inpatients,
age 3 weeks
to 2 years
CMV viraemia in 41%,
associated with being
underweight,
HIV-positive, or
suspected meningitis
Schaftenaar 2014 South
Africa
405
ART-naïve
HIV-positive
children
CMV IgG in 100%,
higher titres associated
with lower CD4+ T cell
count
Manicklal 2014 South
Africa
748 neonates
born to
HIV-infected
mothers
Congenital CMV in
2.9%, associated with
maternal CD4 count
<200 cells/mm3
Mwaanza 2014 Zambia 395 neonates Congenital CMV in
3.8%, maternal HIV
associated with
increased congenital
CMV infection
Hsiao 2013 South
Africa
425 HIV
exposed
infants
CMV viraemia is
associated with
pneumonia in HIV
exposed infants
Zampoli 2011 South
Africa
202 children
with
suspected
PCP
CMV associated
pneumonia more
common in HIV
infected children
Goussard 2010 South
Africa
25
HIV-positive
children with
suspected
PJP
CMV most likely cause
of pneumonia and is
associated with low
CD4 counts and
mortality
Slyker 2009 Kenya 64 infants
born to
HIV-positive
mothers
Maternal CMV
DNAemia is a
significant factor for
mortality in HIV infected
infants
Roxby 2014 Kenya 141 infants
born to
HIV-positive
mothers
66% acquired CMV by
1 year of age
Slyker 2012 Kenya 474 infants
born to
HIV-positive
mothers
CMV induced T cell
activation contributes
to rapid disease
progression in
coinfected infants
The studies summarized are conducted solely in African children and published between
2009 and 2015.
A recent large (n > 6,000) study of HIV infected individuals
in Italy, with high CMV seroprevalence (83.8%), demonstrated
an association between CMV IgG and time to a severe non-AIDS
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FIGURE 3 | Impact of CMV on the immune system. This figure shows the potential for bi-directional interplay between CMV and the immune response. CMV
induces a robust humoral and cellular immune response whilst at the same time has a direct influence on normal immune function. Factors such as poor nutrition and
low weight, crowded living conditions and other herpes virus coinfections also have an impact on immune function and are associated with increased CMV
seroprevalence.
event such as the incidence of cardio/cerebro-vascular disease
or non-AIDS related death (Lichtner et al., 2015). This study
importantly demonstrates the potential for an enhanced disease
burden associated with CMV in HIV-infected individuals,
in whom coinfection does not necessarily result in AIDS-
defining events or well-recognized CMV end-organ disease
such as retinitis, but instead a more subtle interplay leads to
pathology resulting from systemic inflammation and immune
dysregulation. Similarly, other studies report an influence of
CMV in driving early aging (e.g., decline in physical function)
in HIV-infected adults (Erlandson et al., 2015).
Pediatric HIV/CMV Coinfection
As CMV presents a significant risk factor for HIV disease
progression, its impact is likely to be particularly important
in children in settings where both viruses are commonly
acquired in infancy; several studies document the relationship
between CMV coinfection and accelerated HIV progression and
increased mortality in children (Kovacs et al., 1999; Goussard
et al., 2010; Schaftenaar et al., 2014). In Kenya, detection of
maternal CMV DNA in the blood near the time of delivery was
associated with three to four-fold increased mortality in HIV-
infected infants (Slyker et al., 2009). Strikingly, this relationship
remained significant even after controlling for other strong
predictors of infant mortality including maternal CD4+ T cell
count, infant CD4+ T cell percentage, HIV RNA viral load
and maternal death. Studies in HIV infected infants and HIV
exposed uninfected infants also link early CMV acquisition
with growth delay and cognitive impairment (Roxby et al.,
2014).
CD8+ T cell activation has been shown to accompany
acute CMV infection in healthy Gambian infants (Miles et al.,
2007); since this activation is a strong predictor of HIV disease
progression, the acquisition of CMV during primary HIV
infection may accelerate infant HIV progression. Again, there
is evidence for a reciprocal impact of HIV on CMV, whereby
HIV is associated with altered kinetics of CMV replication;
specifically, CMV levels peaked at higher levels and tended to
decline more slowly in HIV-infected infants (Slyker et al., 2009).
Persistent detection of CMV DNA is common in both HIV
infected and HEU infants in the 7–12 month post-infection
period, suggesting incomplete containment of CMV replication
in both these groups of children.
Taken together, these studies suggest that CMV remains a
potentially significant pathogen, independently associated with
worse outcomes in individuals with HIV, even in the setting of
ART. Insight into the epidemiology, pathogenesis, and clinical
impact of CMV is currently a neglected component of our
understanding of the AIDS epidemic. Crucially, developing
insights into the role of CMV in HIV disease could allow
interventions including vaccination or anti-viral therapy for
at-risk individuals.
As ART becomes more widely accessible to this population for
both PMTCT and treatment, it will be important to determine the
impact of maternal and infant ART on CMV epidemiology and
pathogenesis.
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Treatment and Prevention of CMV
CMV disease responds to treatment with a variety of anti-
viral agents including ganciclovir, valganciclovir, cidofovir,
and foscarnet. Access to appropriate diagnosis followed
by anti-viral therapy is difficult in resource-constrained
settings, although there is some precedent for CMV
therapy in patients with CMV viraemia >1000 copies/ml
(Mayaphi et al., 2014), and therapy is clearly advocated for
those in whom invasive end-organ disease is suspected or
confirmed.
As access to both diagnosis and therapy for CMV disease may
be restricted in resource-limited settings, a preventive vaccine is
the most robust future strategy to reduce CMV-related morbidity
and mortality. Two strategies have been employed to develop
CMV vaccines. The first vaccine is live attenuated Towne virus;
this has shown weak protection in a human challenge study
(Plotkin et al., 1989) but failed to provide protection against
infection in CMV seronegative women of childbearing age in
an efficacy study (Adler et al., 1995). The second approach
is an antigen based approach using recombinant gB/MF59
which showed more promise with ∼50% efficacy against CMV
infection in a Phase II trial in seronegative women (Pass et al.,
2009) and ∼50% efficacy in controlling viraemia in seronegative
recipients of sero-positive organ transplants (“R-D+”) (Griffiths
et al., 2011).
Notably, vaccine trials have only been conducted in the
western world but these have resulted in limited success (Wang
and Fu, 2014). An effective CMV vaccine for prevention of
congenital CMV infection is an increasing priority for the West
(Arvin et al., 2004), but the effects of a vaccine could also be
far-reaching in developing countries, particularly in populations
coinfected with HIV.
Conclusions
A high incidence of coinfection occurring early in life, impaired
CMV containment, persistent CMV DNA detection and a
correlation between CMV and HIV peak viral loads suggest that
CMV plays an important role in HIV in sub-Saharan Africa,
as well as in other resource poor settings. Despite compelling
evidence that these infections impact negatively on one another,
this field is relatively neglected, particularly in some of the world’s
most vulnerable populations including neonates and developing
world settings.
Although florid end-organ CMV disease may no longer be
a substantial problem due to the increasing success of ART,
there is growing evidence that its impact as a co-pathogen
remains highly relevant. This may be mediated by immune
activation and systemic inflammation driven by CMV, increasing
the risks of HIV-related morbidity and mortality. There are
also interesting data suggesting an effect of CMV on immune
ontogeny, suggesting it has a role in determining the nature and
efficacy of immune responses to a variety of other infections. This
effect may be particularly pertinent in children.
Significant therapeutic benefits could potentially be derived
from interventions to reduce the incidence of CMV infection,
or to reduce the sequelae of chronic infection including disease
reactivation and long-term immune activation.
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